Veradermics Presents VDPHL01 Data Showing Significant Hair Growth in Two Male Pattern Hair Loss Studies
Bitget2026/11/10 23:26- Veradermics' VDPHL01 met both co-primary efficacy endpoints with high statistical significance in two registration-directed male pattern hair loss studies.
- Twice-daily dosing increased six-month target area hair counts by 36.4 in Study 304 versus 6.6 with placebo.
- Study 302 recorded corresponding increases of 33.0 versus 7.3 with placebo.
- Patient-reported improvement rates with twice-daily dosing reached 68.7% in Study 304 versus 62.9% in Study 302.
- The female Phase 2/3 trial is fully enrolled with 556 participants; initial topline data are expected in the first half of 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Stonex sets initial price target for NXP at $340
Wells Fargo (WFC.US) doubles its IBIT holdings for clients as U.S. institutions significantly increase positions in Q3
According to the 13F report, Wells Fargo's client holdings of IBIT shares have doubled to nearly 50 million shares, equivalent to 30,553 BTC. Institutions such as Goldman Sachs and Bank of America have also significantly increased their holdings of spot bitcoin ETFs. Despite the current bitcoin price falling more than 20% from the quarter-end, institutional enthusiasm for allocation remains strong.

Musk: China is a super fan, Tesla will increase production

Australian job market suddenly stalls! Unemployment rate hits a five-year high, traders move forward Reserve Bank rate cut bets to September next year
Australia's soaring unemployment rate has prompted traders to price in interest rate cuts.
